Biogen Idec Inc BIIB:NASDAQ (Common Stock)

LastChange / % ChangeDividend YieldVolumeAvg Volume (10 day)
316.18 7.11   2.30%1,316,7762.4M
Market data is delayed by at least 20 minutes.
Summary chart showing the current equity's performance of over the past 1 days
  • Advanced Charts
  • Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

As of 12:54 PM ET 10/23/2014

Latest News Headlines for Biogen Idec Inc

Leading Researchers Join Biogen Idec to Advance Drug Discovery for Neurodegenerative Diseases

-- Christopher Henderson and Richard Ransohoff to Lead and Enhance the Company's Neurology Research and Discovery Effort -- CAMBRIDGE, Mass.--(BUSINESS WIRE)--October 23, 2014-- Biogen Idec (NASDAQ: BIIB) today announced that two leading neuroscientists have joined the company to advance its research in neurodegenerative diseases. Christopher Henderson, Ph.D., joins as vice president, Neurology. Richard Ransohoff, M.D., joins as senior research fellow, Neuroimmunology. The addition of these top researchers bolsters Biogen Idec's discovery engine.

Biogen Idec Third Quarter 2014 Revenues Increase -3-

assets 118.7 97.1 371.5 225.2 (Gain) loss on fair value remeasurement of contingent consideration (49.4) (0.1) (46.2) (3.0)

Biogen Idec Third Quarter 2014 Revenues Increase -2-

These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including: our dependence on sales from our principal products; uncertainty of success in execution of our commercialization of new products; failure to protect and enforce our data, intellectual property and other proprietary rights and the diminution of our ability to derive anticipated benefits from our products; difficulties in obtaining or changes in the availability of reimbursement for our products; uncertainty of success in developing other product candidates, including our ability to obtain product approvals in a timely manner or at all for new or current products; the occurrence of adverse safety events with our products; failure to compete effectively due to significant product competition in the markets for our products; dependence on collaborators and other third parties for the development and commercialization of products; problems with our manufacturing processes; failure to manage our growth and execute our growth initiatives; failure to comply with legal and regulatory requirements; the risks of doing business internationally; charges and other costs relating to our properties; risks and uncertainties relating to the timing, outcome and impact of legal, administrative and other proceedings and disputes; fluctuations in our effective tax rate; our ability to attract and retain qualified personnel; uncertainty and potential liabilities relating to product liability and intellectual property claims; the market, interest and credit risks associated with our portfolio of marketable securities; environmental risks; and the other risks and uncertainties that are described in the Risk Factors section of our most recent annual or quarterly report and in other reports we have filed with the SEC.

View more recent headlines

Latest Annual and Quarterly SEC Filings

More Filings
10-K

This report contains detailed information about the company's business finances and management.

10-Q

Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)

Company Background

Biogen Idec Inc. (Biogen Idec) is a global biotechnology company. The Company discovers, develops, manufactures and markets therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. The Company's products include AVONEX, TYSABRI, FAMPYRA, FUMADERM and RITUXAN. In September 2011, the Company acquired from the Dompe Group the noncontrolling interests in its joint venture sales affiliates in Italy and Switzerland. In April 2013, Elan Corporation, plc closed the TYSABRI (natalizumab) Collaboration Transaction with Biogen Idec.

http://www.biogenidec.com/

Loading...

collapse, right-facing arrow indicating collapsed view of sectionOverview

A table providing an overview of the stock
Bid | Size-- | --
Ask | Size-- | --
Price Open314.00
Previous Close309.07
Day High319.35
Day Low311.00
52 Week High3/19/2014 | 358.89
52 Week Low11/8/2013 | 230.25
% Off 52 Week High-11.90%
% Off 52 Week Low37.32%
Beta (5 Yr)1.2
Volatility Avg10/22/2014 | 36.87
10-Day Avg. Volume2,371,953
Market data is delayed by at least 20 minutes.

collapse, right-facing arrow indicating collapsed view of sectionFundamentals

A table providing the fundamentals of the stock
EPS (TTM)6/30/2014 | 9.00
P/E Ratio6/30/2014 | 34.4
Market CapLarge Cap | 74.7B
Shares Outstanding236.15M
Float235.9M

expand, down-facing arrow indicating expanded view of sectionDividends

A table providing information about the dividends of the stock
Dividend Yield--
Ex-Date--
Dividend Announcement--
Date of Record--
Payable-- - --
Payable Date--

expand, down-facing arrow indicating expanded view of sectionShare Statistics

A table providing statistics about shares of the stock
Shares Short3.10M
Short Ratio2.7
Short % of Float1.32%
As of 9/30/2014

Peers Information HelpBIIB Biogen Idec Inc vs. Peers

Peers 
BIIB
Biogen Idec Inc
10.55%
Johnson & Johnson
10.51%
Pfizer Inc.
-7.61%
Merck & Co., Inc.
10.91%
AbbVie Inc
7.74%
BIIB
Biogen Idec Inc
0.00%
Johnson & Johnson
2.77%
Pfizer Inc.
3.67%
Merck & Co., Inc.
3.17%
AbbVie Inc
3.44%
BIIB
Biogen Idec Inc
2.30%
Johnson & Johnson
1.23%
Pfizer Inc.
1.58%
Merck & Co., Inc.
2.25%
AbbVie Inc
3.34%
Compare these stocks